Temasek with Other Investors Park Money into CardioDx

Published

6 years ago

on

August 27, 2012

Singapore’s Temasek Holdings along with other backers such as Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, TPG Biotech and GE Capital committed up to US$ 58 million in CardioDx Inc. in two-tranche equity financing. The investment round includes US$ 30 million currently, and the rest possibly near the end of the year.

According to a recent press release by CardioDx, “this funding positions CardioDx well to capitalize on the significant opportunity to improve the diagnosis of the millions of patients who visit their physicians with symptoms suggestive of obstructive coronary artery disease each year,” said David Levison, the company’s President and Chief Executive Officer. “The favorable Medicare coverage decision that we received earlier this month is a significant milestone that further validates the clinical benefit of and economic rationale for Corus CAD. This additional capital will help us expand our sales force in the U.S., further broaden reimbursement coverage, and support continued investments in research and development of new products.”

PSP Investments Exits Antelliq

On December 14th, Private equity firm BC Partners, Public Sector Pension Investment Board (PSP Investments), and other minority co-investors have signed a definitive agreement with Merck, known as MSD outside the United States and Canada, to sell Antelliq Corporation, a Vitré, France-based provider of digital animal identification, traceability, and monitoring solutions. Upon close, Antelliq will be a wholly owned and separately operated subsidiary within the Merck Animal Health Division. [Content protected for Sovereign Wealth Fund Institute Standard subscribers only.Please subscribe to view content. ]